Loading
Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers.
Isabelle Ray-Coquard was principal investigator of PAOLA-1, the ENGOT/GINECO trial showing maintenance olaparib added to bevacizumab improves progression-free and overall survival in first-line advanced ovarian cancer with homologous recombination deficiency, which made HRD testing a standard part of ovarian cancer care. She leads the French GINECO group and international networks for rare gynaecological cancers.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tags ovarian, parp.
Shares PARP, PARP inhibitors, VEGF / VEGFR, Anti-angiogenic therapy and the tags ovarian, parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tags ovarian, parp.
Shares PAOLA-1 / ENGOT-ov25, PARP, VEGF / VEGFR, Olaparib.
Shares HRD & BRCA testing, PARP, PARP inhibitors, Olaparib.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD), Ovarian cancer and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.